Redoxis is a preclinical CRO with a core competence and experience in models for autoimmune and inflammatory diseases.

They provide a wide range of in vivo and in vitro models for evaluation of efficacy, mechanism of action, bench marking, PK/PD, initial safety and biomarker analysis of novel drugs. Redoxis routinely set up models on demand as a complement to their portfolio of validated models and performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.